+

PE20081874A1 - Composicion farmaceutica que comprende buprenorfina y naloxona - Google Patents

Composicion farmaceutica que comprende buprenorfina y naloxona

Info

Publication number
PE20081874A1
PE20081874A1 PE2008000412A PE2008000412A PE20081874A1 PE 20081874 A1 PE20081874 A1 PE 20081874A1 PE 2008000412 A PE2008000412 A PE 2008000412A PE 2008000412 A PE2008000412 A PE 2008000412A PE 20081874 A1 PE20081874 A1 PE 20081874A1
Authority
PE
Peru
Prior art keywords
naloxone
pharmaceutical composition
composition including
buprenorphine
including buprenorphine
Prior art date
Application number
PE2008000412A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of PE20081874A1 publication Critical patent/PE20081874A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE BUPRENORFINA EN UNA CANTIDAD DE 10 ug Y 8 mm Y NALOXONA, DONDE LA RELACION DE BUPRENORFINA Y NALOXONA SE ENCUENTRA ENTRE 2,1:1 Y 8:1. DICHA COMPOSICION ESTA ADAPTADA PARA SU ADMINISTRACION TRANSDERMICA, TRANSMUCOSA, ORAL-NASAL, UTIL COMO ANALGESICOS
PE2008000412A 2007-03-01 2008-02-29 Composicion farmaceutica que comprende buprenorfina y naloxona PE20081874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703967A GB2447015A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone

Publications (1)

Publication Number Publication Date
PE20081874A1 true PE20081874A1 (es) 2009-01-26

Family

ID=37965734

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000412A PE20081874A1 (es) 2007-03-01 2008-02-29 Composicion farmaceutica que comprende buprenorfina y naloxona

Country Status (16)

Country Link
US (1) US20100168147A1 (es)
EP (1) EP2114453A1 (es)
JP (1) JP2010520185A (es)
KR (1) KR20090115863A (es)
CN (2) CN102670610A (es)
AR (1) AR065581A1 (es)
AU (1) AU2008220573A1 (es)
BR (1) BRPI0807905A2 (es)
CA (1) CA2678675A1 (es)
CL (1) CL2008000610A1 (es)
GB (1) GB2447015A (es)
MX (1) MX2009009133A (es)
PE (1) PE20081874A1 (es)
TW (1) TW200836738A (es)
WO (1) WO2008104737A1 (es)
ZA (1) ZA200905691B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550136B (zh) 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
WO2010008863A1 (en) * 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
EA201991223A1 (ru) 2011-08-18 2019-10-31 Не вызывающие зависимость мукоадгезивные устройства для доставки бупренорфина
SMT202100546T1 (it) 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20140275148A1 (en) * 2013-03-15 2014-09-18 Novus Pharma LLC Orally administrable, self-supporting dissolving film dosage forms
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
DE112015001251T5 (de) 2014-03-14 2017-01-19 Opiant Pharmaceuticals Inc. Nasale Arzneimittelprodukte und Verfahren zu deren Verwendung
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US20250144015A1 (en) 2023-11-06 2025-05-08 Extrovis Ag Pharmaceutical Compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
WO2004014336A2 (de) * 2002-08-09 2004-02-19 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US8236751B2 (en) * 2007-03-07 2012-08-07 The Johns Hopkins University Methods of increasing muscle mass using follistatin-like related gene (FLRG)

Also Published As

Publication number Publication date
JP2010520185A (ja) 2010-06-10
BRPI0807905A2 (pt) 2014-06-17
MX2009009133A (es) 2009-09-03
US20100168147A1 (en) 2010-07-01
EP2114453A1 (en) 2009-11-11
KR20090115863A (ko) 2009-11-09
AR065581A1 (es) 2009-06-17
CL2008000610A1 (es) 2008-09-05
CN101622013A (zh) 2010-01-06
ZA200905691B (en) 2010-10-27
CA2678675A1 (en) 2008-09-04
GB0703967D0 (en) 2007-04-11
CN102670610A (zh) 2012-09-19
WO2008104737A1 (en) 2008-09-04
TW200836738A (en) 2008-09-16
AU2008220573A1 (en) 2008-09-04
GB2447015A (en) 2008-09-03

Similar Documents

Publication Publication Date Title
PE20081874A1 (es) Composicion farmaceutica que comprende buprenorfina y naloxona
TW200738240A (en) Pharmaceutical compositions
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
PE20090168A1 (es) Composiciones farmaceuticas de buprenorfina y naloxona
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX2011006683A (es) Compuestos de madera-plastico que utilzan sobrecapas ionomericas y metodos de fabricacion.
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
UY27720A1 (es) Aroilpiridinonas monocíclicas,
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MY156913A (en) Oral administration of peripherally-acting opioid antagonists
ECSP088889A (es) Forma nueva de administración de racecadotril
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
PE20121537A1 (es) Combinacion de teobromina con un descongestivo
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
SV2011003919A (es) Extrudidos con sustancias activas con forma de agujas

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载